Search Results - "DE LOCHT, M"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
  2. 2
  3. 3

    Mucormycosis during deferoxamine therapy is a siderophore-mediated infection : in vitro and in vivo animal studies by BOELAERT, J. R, DE LOCHT, M, VAN CUTSEM, J, KERRELS, V, CANTINIEAUX, B, VERDONCK, A, VAN LANDUYT, H. W, SCHNEIDER, Y.-J

    Published in The Journal of clinical investigation (01-05-1993)
    “…This study investigates the pathophysiology of mucormycosis caused by Rhizopus, which has been reported in 46 dialysis patients, while treated with…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect by Boelaert, Johan R., Van Cutsem, Jan, de Locht, Marielle, Schneider, Yves-Jacques, Crichton, Robert R.

    Published in Kidney international (01-03-1994)
    “…Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Deferoxamine (DFO), when used in dialysis…”
    Get full text
    Journal Article
  15. 15

    Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus by de Locht, M, Boelaert, J R, Schneider, Y J

    Published in Biochemical pharmacology (18-05-1994)
    “…Mucormycosis caused by the fungus Rhizopus has been documented in iron overloaded patients and more particularly in dialysis patients, both when treated with…”
    Get more information
    Journal Article